Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:15 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 587 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Gram-Negative Bacterial Infections Clear all

Conditions: Gonorrhea of Pharynx, Gonorrhea
Interventions: Aztreonam; Drug
Lead sponsor: University of Washington; Other
Eligibility: 16 Years and older
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Meningococcal Disease
Interventions: MenACWY-CRM; Biological
Lead sponsor: Novartis Vaccines; Industry
Eligibility: 11 Years to 21 Years
Enrollment: 55,397 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2015
U.S. locations: 3
States / cities: Riverside, California • San Diego, California • Valley Annex, 16994 E. Valley Blvd., Fontana, California

Conditions: Iron Deficiency
Interventions: Quadruple sequential Helicobacter pylori eradication + iron sulfate, Quadruple sequential Helicobacter pylori eradication therapy, Ferrous sulfate, Placebo; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 36 Months to 120 Months
Enrollment: 125 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Syphilis
Interventions: Abbott Laboratories Determine test for syphilis, Investigational syphilis immunochromatographic strip test; Device
Lead sponsor: Centers for Disease Control and Prevention; Federal
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2009
U.S. locations: 5
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 2 more

Conditions: Gonorrhea
Interventions: Zoliflodacin, high calorie, high fat breakfast; Drug · Other
Lead sponsor: Drugs for Neglected Diseases; Other
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Opioid Use Disorder, HIV Infections, Chlamydia, Gonorrhea, Syphilis, Trichomonas
Interventions: Mobile Van Clinic; Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Lyme Disease
Interventions: VLA15, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years and older
Enrollment: 1,712 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 19
States / cities: Bangor, Maine • Worcester, Massachusetts • Flemington, New Jersey + 13 more

Conditions: Acinetobacter Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Lyme Disease
Interventions: PCR based assay, Serology based assay, Tcell based assay; Diagnostic Test
Lead sponsor: Oxford Immunotec; Industry
Eligibility: 5 Years and older
Enrollment: 410 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 60
States / cities: Redding, California • New London, Connecticut • Norwalk, Connecticut + 53 more

Conditions: Meningococcal Infections, Meningitis
Interventions: Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined; Biological
Lead sponsor: Sanofi Pasteur, a Sanofi Company; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 170 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2004
U.S. locations: 1
States / cities: East Stroudsburg, Pennsylvania

Conditions: Sexually Transmitted Diseases, Gonorrhea, Chlamydia, Syphilis, HIV
Interventions: Motivational interviewing and specimen self-collection; Behavioral
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Urinary Tract Infections
Interventions: LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Fresno, California • Lancaster, California • Los Angeles, California + 13 more

Conditions: Chlamydia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 15 Years to 35 Years · Female only
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Infection
Interventions: STD Diagnostic Kit (Identigene); Device
Lead sponsor: Identigene; Industry
Eligibility: 14 Years and older
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Cystic Fibrosis, Chronic Bronchitis
Interventions: IV amikacin, PO azithromycin, IV ceftazidime, PO ciprofloxacin, IV meropenem, IV piperacillin-tazobactam, IV ticarcillin-clavulanate, IV tobramycin; Drug
Lead sponsor: Seattle Children's Hospital; Other
Eligibility: 14 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2007
U.S. locations: 8
States / cities: Iowa City, Iowa • St Louis, Missouri • Cincinnati, Ohio + 4 more

Conditions: Meningococcal Disease, Pregnancy, Infections, Meningococcal
Interventions: Meningococcal quadrivalent CRM-197 conjugate vaccine; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: Female only
Enrollment: 93 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 2
States / cities: Wilmington, North Carolina

Conditions: Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation, Pseudomonas Aeruginosa Infection
Interventions: Ceftolozane/Tazobactam; Drug
Lead sponsor: Joseph L. Kuti, PharmD; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 4
States / cities: Hartford, Connecticut • Indianapolis, Indiana • Chapel Hill, North Carolina + 1 more

Conditions: Urinary Tract Infection, Fluoroquinolone, Bacteremia
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Cryptogenic Cirrhosis, Cryptogenic Chronic Hepatitis
Interventions: skin punch biopsy collection, Blood collection, Urine sample collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lyme Disease
Interventions: VLA15, Saline; Biological · Other
Lead sponsor: Pfizer; Industry
Eligibility: 5 Years and older
Enrollment: 12,546 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 82
States / cities: Essex, Connecticut • Ledyard Center, Connecticut • New London, Connecticut + 67 more

Conditions: Tuberculosis (TB)
Interventions: GSK's candidate Mycobacterium tuberculosis vaccine 692342; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2004
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Gram-Negative Bacterial Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Enterobacteriaceae Infections
Interventions: Not listed
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years and older
Enrollment: 450 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Trachoma
Interventions: community surveillance and re-treatment; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Months to 7 Years
Enrollment: 2,700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Aztreonam for Pharyngeal Gonorrhea

Safety of MenACWY-CRM Vaccination in Adolescents

Helicobacter Pylori Eradication Trial to Reduce Iron Deficiency in Children

Multi-site Study of Rapid Diagnostic Syphilis Assays

Study to Investigate Effect of Food and Safety of a New Formulation of Zoliflodacin

Combination Primary Care and Prevention Services for Women Who Inject Drugs and Exchange Sex in Seattle, Washington

A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine

Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol

Lyme Test Indication Combinations (LyTIC) Study

Safety and Immunogenicity of Intradermal Versus Subcutaneous Doses of Menomune®

Zenyth: Motivational Interviewing-based Telehealth Intervention for Bacterial Sexually Transmitted Infection Screening

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Antigen-Specific Cell Mediated Immune Response to Chlamydia Trachomatis

Identigene STD Test Collection Kit Validation Study

Standard vs. Biofilm Susceptibility Testing in Cystic Fibrosis (CF)

Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry

Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients

Clinical Impact of Fluoroquinolone Resistance in Bacteremia Caused by Gram-Negative Bacilli of Urinary Tract Origin

Bartonella in Liver Transplant Patients

An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15)

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

Gram Negative Bacteremia, Risk Factors for Failure of Therapy

Risk Factors for Piperacillin/Tazobactam Resistance in Extended-Spectrum Beta-Lactamase (ESBL) Producing Organisms

Study of Three Alternatives for Mass Treatment in Trachoma Villages of Tanzania